Gregal

Gregal is a prescription medication that contains the active ingredient tiotropium bromide, an anticholinergic bronchodilator. It is supplied in an oral dosage form and is marketed in the European Union. Tiotropium bromide works as a long‑acting muscarinic antagonist to help keep the airways open in patients with chronic respiratory conditions. The medication is classified under ATC code R03BB04 and is prescribed for therapy in chronic obstructive pulmonary disease and asthma.

Gregal is indicated for the long‑term management of certain chronic respiratory diseases.

- Chronic obstructive pulmonary disease (COPD) – helps reduce the frequency of exacerbations and improves overall lung function. - Asthma – used as an add‑on therapy for patients whose symptoms are not fully controlled with inhaled corticosteroids. - Maintenance treatment – provides once‑daily bronchodilation to improve breathing capacity and lessen shortness of breath. - Adults with stable disease – suitable for patients who require a long‑acting anticholinergic agent. - May be considered when inhaled therapy adherence is a concern – oral administration offers an alternative route.

The safety profile of Gregal includes both common and less frequent adverse reactions observed in clinical use.

Common: - Dry mouth - Throat irritation - Cough - Upper respiratory tract infection

Serious: - Paradoxical bronchospasm - Severe allergic reaction (e.g., angioedema, rash) - Urinary retention in patients with prostate enlargement

Before prescribing Gregal, clinicians should evaluate patient history and consider specific safety considerations.

- Assess for known hypersensitivity to tiotropium bromide or other anticholinergic agents. - Use caution in patients with narrow-angle glaucoma or severe urinary retention. - Monitor renal function, as reduced clearance may increase systemic exposure. - Avoid initiating therapy in individuals with acute bronchospasm; stabilize condition first. - Educate patients on proper oral administration technique to minimize local irritation. - Review pregnancy and lactation status, as safety data are limited. - Consider age‑related dose adjustments for elderly patients with comorbidities.

Gregal may interact with other medicines, and certain combinations should be avoided or used with caution.

Avoid: - Other anticholinergic drugs (e.g., ipratropium) – additive antimuscarinic effects may increase risk of dry mouth and urinary retention. - Strong CYP3A4 inhibitors – may raise systemic levels of tiotropium.

Use with caution: - Beta‑agonists – concurrent use may enhance bronchodilation but requires monitoring for tachycardia. - Diuretics – potential for increased dehydration and electrolyte imbalance. - Medications affecting renal excretion (e.g., cimetidine) – may alter tiotropium clearance.